Dr. David Horn Solomon, PhD

Chairman of the Board

David Horn Solomon has extensive experience in the biotech sector as a CEO and board member, as well as an investor. He was previously the CEO of Silence Therapeutics (LON: SLN), a UK-listed biotech company developing RNAi-based therapeutics to treat conditions with a high unmet medical need.

Previously, David served as CEO of Akari Therapeutics (NASDAQ: AKTX), Managing Partner at Sund Capital, a specialized Nordic-focused healthcare investment fund, and CEO of Bionor Pharma ASA. From 2008 to 2015, he was CEO of Zealand Pharma A/S (NASDAQ: ZEAL), during which time Adlixin®, the company’s lead product for the treatment of type II diabetes, was approved in the US. Adlixin® is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®.

From 2003 to 2006, David headed healthcare investments at Carrot Capital Healthcare Ventures in New York City. He is a former member of the board of directors of TxCell SA (acquired by Sangamo in 2018), Onxeo SA (Euronext Paris: ONXEO) and was Chairman of Promosome LLC (La Jolla, CA).

David studied at Weill Cornell Medicine of Cornell University where he earned his Ph.D and served on the faculty of the College of Physicians and Surgeons at Columbia University, both located in New York City.

Didier Laurens

Chief Executive Officer

Didier Laurens has extensive experience in the finance and healthcare sectors where he has served as CFO and financial analyst specializing in the pharma/biotech sector. He was previously CFO of Ecential Robotics, a private medical technology company, which markets robotic solutions for spine surgery.

Didier was previously CFO of Pixium Vision (Euronext Paris: ALPIX), interim CFO of Korian (Euronext Paris: KORI) after having been its Director of Financing, Treasury and Investor Relations.

From 1999 to 2013, Didier was a financial analyst specialized in the healthcare sector at Oddo BHF and Société Générale. He also managed the mid-cap equity research of these two banks and participated in numerous IPOs in the healthcare sector.

Didier holds a Pharm D. in pharmacy (Paris V), a post-graduate diploma in galenic pharmacy and is a graduate of the French Society of Financial Analysts (CIIA / SFAF), of which he was one of the directors.

André Ulmann, MD, PhD

Medical Director


André Ulmann’s career spans some thirty years in research and the pharmaceutical industry, as well as in medical practice. He serves as an active advisor to Advicenne from conception through drug development.

André is currently a Director of HRA Pharma, which he founded and managed until 2009 before assuming the presidency. In 1999, HRA Pharma launched Norlevo, better known as the “morning-after pill.” Norlevo is now available in more than fifty countries and has made HRA Pharma a pioneer in emergency contraception. Under André’s leadership, HRA Pharma has become a socially-conscious pharmaceutical company that designs and develops medical products and devices for the treatment of rare diseases and unmet medical needs.

André is a MD, and began his career practicing Nephrology at Hôpital Necker (Paris, France).


Catherine Dunand

Catherine Dunand has held several executive posts in the pharmaceutical industry, among them, International Marketing Manager, Head of International Marketing and Head of International Profit Centers. Working with companies such as Roussel Uclaf and Hoechst Marion Roussel (now parts of Sanofi), Catherine has also conducted several mergers and acquisitions assignments, and reorganization projects.

Following her work in the pharmaceutical industry, she served as the Chief Executive Officer of several small- and mid-cap corporations, leading two successive leveraged buyouts.

For the last eight years, Catherine has dedicated herself to consulting and non-executive assignments for growing SMEs, including family-owned companies, listed companies and private equity funds. She also holds minority stakes in several private equity investments.

Following the sale of the pharmaceutical company HRA, Catherine helped to found Cemag Invest, a family office investing in healthcare and business-to-business services. She currently serves as the company’s CEO.

Catherine holds degrees from Ecole Centrale de Lyon and INSEAD (MBA), and received her non-executive director certification from Sciences Po/IFA (Institut Français des Administrateurs).

Charlotte Sibley

Charlotte Sibley’s career in the healthcare industry spans forty years, and includes contributing her expertise in market research at Pfizer, and in the medical device sector at Johnson & Johnson. Over the course of her career, Charlotte has also expanded her expertise to the areas of global pharma at Bristol-Myers Squibb and Pharmacia (now Pfizer), biotech at Millennium Pharmaceuticals (now Takeda Oncology), and consumer products at Lipton. She established the US operations for a leading UK-based market research company, achieving profitability in eighteen months in a highly competitive environment. Charlotte also worked as a security analyst for the pharmaceutical industry at Donaldson, Lufkin & Jenrette in New York.

Charlotte was named 2008 Woman of the Year by the Healthcare Businesswomen’s Association in recognition of her leadership, business expertise and mentoring. She was also among those named in PharmaVoice’s Most Inspiring People in Pharma in 2006. She serves on the Boards of Directors of privately held Taconic Biosciences, Inc. and Fort Hill Company. Through 2014 she was a member of the Board of American Pacific Corporation (NASDAQ: AMPAC), a leading custom manufacturer of pharmaceutical ingredients and propulsion products.

Charlotte holds an MBA in Finance and Marketing from the University of Chicago Booth Graduate School of Business, and is a National Association of Corporate Directors (NACD) Board Leadership Fellow and Governance Fellow.

Hege Hellstrom

Hege Hellstrom has been a member of the Board of Directors of Advicenne as an independent director since May 2020. She has over 30 years of experience in the medical device, pharmaceutical and biotech industry. She is founder and partner of an investment and consultancy company, Belnor bvba and serves currently as a non-Executive Board member in Oasmia AB (OASM.ST) and Camurus AB (CAMX.ST), both Swedish biotech companies. She is also a board member of Jane Goodall Institute Belgium.

From 2013 to 2018, she was President of Sobi, a Swedish biotech company specialized in rare, genetic diseases such as Haemophilia and metabolic disorders. She orchestrated several successful country launches of products such as Elocta® and Alprolix®, products treating Haemophilia patients.

Prior to Sobi, Hege worked 11 years in Genzyme, a Boston based company where she was Head of the Renal and Endocrine Business Unit for Europe, JAPAC and Latin-America, as well as General Manager for Benelux. When Sanofi acquired Genzyme, she became Global Head of the Cardiovascular Unit of Sanofi.

From 1989 to 2002, Hege worked at Baxter in Norway and Belgium. During her career she has had commercial experience from pre-launch and launch, to end of lifecycle management of a wide range of products in many disease areas.

Hege has a B.Sc as a Medical Laboratory Scientist from Oslo Metropolitan University, Norway and has completed an Executive Board programme at INSEAD.

Jean-Michel Petit

Jean-Michel Petit heads the venture capital practice of IRDI Gestion, where he manages the seed fund IRDInov, investing in start-ups located in the southwest of France. He serves on the boards of several portfolio companies such as Gamamabs, Fineheart, EnobraQ, Telecom Design, Ademtech and LDL Technology. Before joining IRDI Gestion, Jean-Michel spent four years at CDP Capital as part of the Life Sciences venture capital team, based initially in Montréal and then in Paris, where he made a range of international investments (mostly in the US). Prior to CDP Capital, he worked for a regional fund based in Montréal, Canada.

Jean-Michel graduated from Chimie ParisTech and holds an M.Sc. from Montréal University, as well as an MBA from McGill University (Montréal, Canada).

Philippe Boucheron

Philippe Boucheron has more than twenty years of life science investment experience and currently serves as Deputy Chief of Life Sciences Investment at Bpifrance.

From 1993 to 1996, Philippe worked as an associate at BioCapital LP, one of the largest Canadian venture capital funds focusing on healthcare. In 1997, he joined the mid-cap equity research team at ING Barings Ferri, Paris, which he directed until 2000 and where he spent a significant part of his time following French and European listed biotech companies.

In 2000, he co-founded Bioam Funds, dedicated to early-stage life science investments, serving as Investment Manager, then, in 2004, as Managing Partner. After the merger of Bioam with CDC Entreprises in July 2010, Philippe joined the CDC Entreprises life sciences team as Investment Manager.

CDC Entreprises, FSI and Oséo merged to create Bpifrance in 2013. Since then, Philippe has served as Deputy Chief of the Life Sciences Investment Business Unit and sits on the company’s Investment Committee. He also serves on the boards of Ademtech, Integragen, SSI, ART, Supersonic Imagine and CorWave.

Philippe holds degrees in Biochemical Engineering and Microbial Genetics from the National Institute of Applied Sciences in Toulouse (INSA), an MSc in Biochemical Engineering from Ecole Polytechnique (Montréal, Canada) and an MBA from INSEAD.

Thibaut Roulon, PhD

Thibaut Roulon is currently Investment Director of Life Science Investments at Bpifrance. A scientist by training, he has been an investor since 2005, when he joined Bioam Gestion, a venture capital firm investing in life sciences companies. In 2010, Bioam merged with CDC Entreprises, a leading French private equity firm. Thibaut is responsible for managing investments in life sciences companies through Bioam and InnoBio funds.

Thibaut started his career as a scientist at Anosys Inc. (Menlo Park, CA, USA), a company developing cancer immunotherapeutics. He is a graduate of the Ecole Centrale de Paris and holds a PhD from Pierre and Marie Curie University.

Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

4 + 2 =

© 2020 Advicenne